Saxenda

Excellus BlueCross BlueShield says GLP-1 drugs for diabetes will remain on formulary, countering reports of a blanket halt. Effective January 1, 2026, three GLP-1s for weight loss—Wegovy, Zepbound, and Saxenda—will be removed from covered lists for certain plans, though members can seek exceptions if prescribers verify criteria. The insurer cites Pharmacy & Therapeutics Committee review […]